NPI-001 for preserving photoreceptors in RP with Usher syndrome

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a phase 3, randomized, placebo-controlled trial evaluating NPI-001 for preserving photoreceptors in adults with RP associated with Usher syndrome. Participants will take either NPI-001 or placebo twice daily for 24 months and undergo nine clinic visits for safety and efficacy assessments. Key measures include photoreceptor preservation and safety outcomes. Eligible individuals must have RP with Usher syndrome, sufficient EZ width, detectable MAIA points, and stable concurrent medications. Exclusion criteria include other retinal diseases, recent intraocular surgery, and conditions that could affect fixation or vision.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Able to comprehend and willing to sign an informed consent form (OCF) and adhere to the study protocol.
2. Diagnosed with RP associated with Usher syndrome.
3. EZ width ≥ 500 microns, which includes the fovea in each eye at Visit 1.
4. All edges of the EZ area in both eyes can be visualized at Visit 1 (Screening).
5. Have at least 20 detectable points on the MAIA grid in at least one eye at the Screening and Baseline visits (same eye for both visits).
6. On stable dose of medications associated with other conditions for at least one month.
7. Willing to use contraception during study (for anyone of childbearing potential).

Exclusion Criteria:

1. Concurrent retinal pathologies that result in vision loss or inability to fixate.
2. Intraocular surgery within the last two months or capsulotomy within the last month.
3. Current or history of uveitis, Coat's disease, diabetic retinopathy, glaucoma, herpes simplex of the eye, or currently has a cataract that prevents visualization of the posterior pole.
4. Likely to require cataract surgery within the next 12 months.
5. Unstable fixation during microperimetry in either eye at either Screening or Baseline visits.
6. Use of any other investigational new drug, or participation in another clinical trial within 12 weeks before the start of study treatment.
7. Use of N-acetylcysteine containing products in the previous 30 days prior to the baseline visit or unwilling to refrain from such supplements for the duration of the study.
8. Chronic liver or kidney disease, cystic fibrosis, severe asthma, or chronic obstructive pulmonary disease (COPD), history of thrombocytopenia not due to a reversible cause, or other blood dyscrasia.
9. Suspected liver dysfunction determined by having alanine aminotransferase (ALT), aspartate aminotransferase (AST), or bilirubin values \> 1.5 X the upper limit of normal (ULN) at screening.
10. Platelet or hemoglobin values \< 100 at screening.
11. History of known sensitivity to N-acetylcysteine or similar thiol compounds or any ingredients of NPI-001.
12. History of hypersensitivity to any medication or food resulting in systemic symptoms.
13. History of cancer (other than non-melanoma skin cancer) diagnosed or requiring treatment within the past 2 years.
14. Pregnant women or women planning to become pregnant in the next 25 months or men with partners planning to become pregnant in the next 25 months.
15. Lactating women who are breast-feeding.
16. Potential participant lives in the same household as a current participant in this study.
17. Subjects who are unwilling or unable to refrain from donation of blood from 30 days prior to Screening, plasma from 2 weeks prior to Screening, or platelets from 6 weeks prior to Screening until 56 days following the last study drug dose administered.
18. Inability to provide blood samples, including difficulty with venous access.
19. Any reason, in the opinion of the Principal Investigator, the participant should not participate.

Where it's running

• Retina Foundation of the Southwest
  Dallas, Texas, United States Recruiting

Study contacts

• Study coordinator: Nacuity Pharmaceuticals
• Email: info@nacuity.com
• Phone: +1-817-336-3000

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Short-term effects of transcorneal electrical stimulation on visual performance

  This study will see if a 30-minute session of transcorneal electrical stimulation with the OkuStim device produces short-term vision improvements in adults with retinitis pigmentosa or similar retinal degenerations who already use the device.

  Recruiting Okuvision GmbH · Frankfurt am Main · NCT07548944

• Investigating OpCT-001 for treating primary photoreceptor disease

  This study is testing a new treatment called OpCT-001 to see if it can safely help adults with primary photoreceptor diseases, like Retinitis Pigmentosa and Usher Syndrome, improve their vision.

  Recruiting at 5 sites Phase 1/2 BlueRock Therapeutics · Los Angeles, California and 4 other locations · NCT06789445

• Eye gene therapy for retinitis pigmentosa with a single RTx-015 injection

  A single eye injection of RTx-015 is being tested to see if it helps people with retinitis pigmentosa.

  Recruiting at 6 sites Phase 2/3 Ray Therapeutics, Inc. · Phoenix, Arizona and 13 other locations · NCT07901751

• Gene therapy SPVN20 for advanced rod-cone dystrophy

  This study tests different doses of SPVN20 injected into the eye to see if it is safe and can help people with advanced rod-cone dystrophy.

  Recruiting at 3 sites Phase 1/2 SparingVision · Ghent and 2 other locations · NCT07807111

• Pitavastatin in PLGA Nanoparticles for Retinitis Pigmentosa safety test

  This Phase 1 study tests whether an intravenous pitavastatin nanoparticle formulation is safe for adults with retinitis pigmentosa.

  Recruiting Phase 1 Kyushu University · Fukuoka · NCT07774975

• Brain stimulation to improve orientation and mobility in adults with vision impairment

  This pilot test checks if a non-invasive brain stimulation method can help people with constricted visual fields move around more easily using a cane and other cues.

  Recruiting University of Waterloo · Waterloo, Ontario · NCT07341763

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.